Study of Topotecan and Etoposide for Cancer Treatment
Author Information
Author(s): VMM Herben, WW ten Bokkel Huinink, AC Dubbelman, IAM Mandjes, Y Groot, DM van Gortel-van Zomeren, JH Beijnen
Primary Institution: Antoni van Leeuwenhoek Hospital/Netherlands Cancer Institute
Hypothesis
To determine the maximum tolerated dose and dose-limiting toxicities of topotecan in combination with etoposide.
Conclusion
The combination of topotecan and etoposide resulted in significant neutropenia as the main dose-limiting toxicity.
Supporting Evidence
- Neutropenia was the principal dose-limiting toxicity observed.
- 64% of patients had stable disease for at least 4 months.
- A partial response was observed in a patient with metastatic ovarian carcinoma.
- Patients received topotecan and etoposide in a sequential regimen.
Takeaway
Doctors tested a new cancer treatment using two drugs, topotecan and etoposide, and found that it could make patients' blood counts drop too low, which is a problem.
Methodology
Patients with advanced solid tumors received topotecan intravenously followed by oral etoposide, with dose levels escalated to find the maximum tolerated dose.
Limitations
The study was limited by the high incidence of neutropenia and the inability to escalate doses due to bone marrow recovery issues.
Participant Demographics
30 patients, 11 men and 19 women, median age 54 years.
Want to read the original?
Access the complete publication on the publisher's website